Improving outcomes for patients with chronic hepatitis B

Hepatology Research

Volumn 37, Issue SUPPL. 1, 2007, Pages

  Gish, Robert G ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Entecavir; Hepatitis B; Nucleoside analog; Pegylated interfero

Indexed keywords

16ALPHA BROMOEPIANDROSTERONE; 2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR DIPIVOXIL; ALAMIFOVIR; ALPHA2B INTERFERON; AMDOXOVIR; ANTIVIRUS AGENT; BAM 205; BAY 41 409; EHT 899; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LIVER ENZYME; MIV 210; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; ROBUSTAFLAVONE; TELBIVUDINE; TENOFOVIR DISOPROXIL; THYMOSIN ALPHA1; TYZEKA; UNINDEXED DRUG; VALTORCITABINE; VIRUS DNA;

CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DNA DETERMINATION; DRUG CHOICE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENZYME BLOOD LEVEL; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK REDUCTION; SEROLOGY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS CARRIER; VIRUS CELL INTERACTION; VIRUS DETECTION; VIRUS GENE; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 34447631210     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00108.x     Document Type: Conference Paper

References (78)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23: 39-46.
3. Gish RG, Gadano AC. Chronic hepatitis B: Current epidemiology in the Americas and implications for management. J Viral Hepat 2006; 13: 787-98.
4. Moyer LA, Mast EE. Hepatitis B: Virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. Am J Prev Med 1994; 10 (Suppl.): 45-55.
5. Craxi A, Antonucci G, Camma C. Treatment options in HBV. J Hepatol 2006; 44: S77-83.
6. Marcellin P, Boyer N, Asselah T. Medical therapy of patients affected by HBeAg-negative chronic hepatitis B. Minerva Gastroenterol Dietol 2006; 52: 23-38.
7. Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 2005; 22: 519-28.
8. Papatheodoridis GV, Dimou E, Dimakopoulos K et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-9.
9. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11: 432-8.
10. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-73.
11. Gish RG, Chang TT, De Man RA et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg (+) chronic hepatitis B patients (study ETV-022). Hepatology 2005; 42 (Suppl. 1): 267A.
12. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999; 56: 570-80.
13. Lok AS. New treatment of chronic hepatitis B. Semin Liver Dis 2004; 24 (Suppl. 1): 77-82.
14. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
15. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12months with lamivudine. J Hepatol 2000; 32: 300-6.
16. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-96.
17. National Institutes of Health. Management of Hepatitis B: 2006. 6-8 April 2006, Bethesda, Maryland. Washington: NIH, 2006.
18. Perkins JD. Infection by proxy: The role of chimeric mice in HBV and HCV research. Liver Transpl 2006; 12: 323.
19. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004; 101: 6669-74.
20. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
21. Barranco C. Vaccination prevents perinatal transmission of hepatitis B virus. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 243.
22. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24: 572-7.
23. Inaba S, Ito A, Miyata Y, Tadokoro K, Kikuchi S. Effectiveness of hepatitis B vaccination. Infect Control Hosp Epidemiol 2006; 27: 101-2.
24. Ghendon Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine 1990; 8 (Suppl.): S129-33.
25. Hallauer J. VHPB: Summary of strategies and recommendations. Viral Hepatitis Prevention Board. Vaccine 1995; 13 (Suppl. 1): S61-3.
26. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13 (Suppl. 1): S47-9.
27. Safary A, Beck J. Vaccination against hepatitis B: Current challenges for Asian countries and future directions. J Gastroenterol Hepatol 2000; 15: 396-401.
28. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-9.
29. Chang MH. Hepatitis B: Long-term outcome and benefits from mass vaccination in children. Acta Gastroenterol Belg 1998; 61: 210-13.
30. Chang MH. Hepatocellular carcinoma in children. Zhonghua minguo xiao er ke yi xue hui za zhi 1998; 39: 366-70 (in Chinese).
31. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 1408-15.
32. Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003; 98: 2261-7.
33. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
34. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature. Hepatology 2003; 37: 1309-19.
35. Fattovich G, Rugge M, Brollo L et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167-72.
36. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26: 1338-42.
37. Bortolotti F, Guido M, Bartolacci S et al. Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study. Hepatology 2006; 43: 556-62.
38. Manno M, Camma C, Schepis F et al. Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756-63.
39. Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
40. Lok AS, McMahon BJ. AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines. Rom J Gastroenterol 2004; 13: 150-4.
41. EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002. Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38: 533-40.
42. EASL. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. September 14-16, 2002. Geneva, Switzerland. J Hepatol 2003; 39 (Suppl. 1): S1-235.
43. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87-106.
44. Locarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679-93.
45. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-62.
46. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-27.
47. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
48. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
49. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29: 1863-9.
50. Wolters LM, Hansen BE, Niesters HG et al. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol 2002; 37: 253-8.
51. Wolters LM, Hansen BE, Niesters HG, Dehertogh D, De Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002; 37: 137-44.
52. Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, De Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 2002; 22: 121-6.
53. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-19.
54. Locarnini S. Hepatitis B viral resistance: Mechanisms and diagnosis. J Hepatol 2003; 39 (Suppl. 1): S124-32.
55. Ito K, Tanaka Y, Orito E et al. Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection. Clin Infect Dis 2004; 38: 490-5.
56. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
57. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-80.
58. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
59. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
60. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
61. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-51.
62. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2.
63. Honkoop P, Niesters HG, De Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26: 1393-5.
64. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-34.
65. Yeon JE, Yoo W, Hong SP et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488-95.
66. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41: 1444-8.
67. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998; 42: 3200-8.
68. De Man RA, Wolters LM, Nevens F et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001; 34: 578-82.
69. Lai CL, Rosmawati M, Lao J et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831-8.
70. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005; 365: 123-9.
71. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-75.
72. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: A cost-effectiveness analysis. Ann Intern Med 2005; 142: 821-31.
73. Bonino F, Brunetto MR, Rizzetto M, Will H. Hepatitis B virus unable to secrete e antigen. Gastroenterology 1991; 100 (4): 1138-41.
74. Cossart YE. Australia antigen and hepatitis in renal units. Proc Eur Dial Transplant Assoc 1972; 9: 235-42.
75. Davis HL. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt Sinai J Med 1999; 66: 84-90.
76. Yim HJ, Lok AS-F. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-81.
77. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. NEJM 2004; 351: 1206-17.
78. Wong J. Cost of Antiviral Therapy of Chronic Hepatitis B. In: National Institutes of Health. Management of Hepatitis B: 2006. 6-8 April 2006, Bethesda, MD. Washington: NIH, 2006.